9. Commitments Lease The Company leases office space under a noncancelable operating lease. In November 2012, the Company amended the lease for additional square footage and on February 3, 2014, the Company signed an amendment to its facility lease for additional space. In addition, on February 28, 2014 the Company entered into lease assignment, which provided further additional space. The lease is subject to charges for common area maintenance and other costs. The lease and the lease assignment expire in August 2016 with one three-year extension period. The lease amendment for the additional space expires on November 30, 2014. Provisions of the lease provide for abatement of rent during certain periods and escalating rent payment during the initial and extended lease terms. Rent expense is being recorded on straight line basis over the life of the lease. Future minimum payments required under the lease are summarized as follows (in thousands): Year Ending December 31: 2014 (Nine months remaining) 227 2015 219 2016 149 Total minimum lease payments $ 595 Patent Assignment Agreement In September 2011, the Company entered into a patent assignment agreement with Concert Pharmaceuticals, Inc. (Concert) pursuant to which Concert assigned to the Company a U.S. patent application relating to deuterated pirfenidone. Under the terms of the agreement, Concert is eligible to receive certain royalty payments (the Royalty Payments), equal to a percentage in the low single digits of net sales in the United States invoiced by the Company or any of its affiliates with respect to certain pharmaceutical products containing deuterated pirfenidone. If the Company sells to another party all of its U.S. rights to certain deuterated pirfenidone products or if the Company grants to another party a license to sell certain deuterated pirfenidone products in the United States, Concert will receive an amount (the Sublicense/Sale Payments), equal to a percentage in the teens of any proceeds the Company receives therefrom that are attributable